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Rationale: Acute lung injury (ALI) is an important cause ofmorbidity
and mortality, with no currently effective pharmacological thera-
pies. Neutrophils have been specifically implicated in the patho-
genesis of ALI, and there has been significant research into the
mechanisms of early neutrophil recruitment, but those controlling
the later phases of neutrophil emigration that characterize disease
are poorly understood.
Objectives: To determine the influence of peripheral blood mono-
cytes (PBMs) in established ALI.
Methods: In a murine model of LPS-induced ALI, three separate
models of conditional monocyte ablation were used: systemic
liposomal clodronate (sLC), inducible depletion using CD11b diph-
theria toxin receptor (CD11b DTR) transgenic mice, and antibody-
dependent ablation of CCR2hi monocytes.
Measurements andMain Results: PBMsplay a critical role in regulating
neutrophil emigration in established murine LPS-induced lung in-
jury. Gr1hi andGr1lo PBM subpopulations contribute to this process.
PBMdepletion is associatedwith a significant reduction inmeasures
of lung injury. The specificity of PBMdepletionwasdemonstratedby
replenishment studies inwhich theeffectswere reversedbysystemic
PBM infusion but not by systemic or local pulmonary infusion of
mature macrophages or lymphocytes.
Conclusions: These results suggest that PBMs, or the mechanisms by
which they influence pulmonary neutrophil emigration, could rep-
resent therapeutic targets in established ALI.
Keywords: acute lung injury; LPS; monocytes; neutrophils
The innate inflammatory response is geared to the clearance of
pathogens, but excessive and persistent granulocyte accumula-
tion is detrimental to the host (1). Acute lung injury (ALI) and
its severe form, acute respiratory distress syndrome (ARDS), are
characterized by neutrophil-mediated lung injury, the most
common etiology being severe sepsis (2). Neutrophil-mediated
lung injury of the epithelial/endothelial interface and conse-
quent vascular leak are the hallmarks of ALI/ARDS (2–4).
There are 200,000 cases per year of ALI in the United States,
with a mortality of approximately 40% (2). No pharmacologi-
cal agents have been shown convincingly to affect mortality.
There is thus a pressing need to define critical mediators of
neutrophil recruitment and to implement specific, mechanism-
based therapeutic interventions.
The neutrophilic response in ALI has been described as oc-
curring in two distinct phases (5): an initial “recruitment phase”
mediated by chemokines followed by a “persistent phase” of neu-
trophil recruitment, possibly mediated in part by stromal-derived
factor-1 (SDF-1/CXCL12) (5). Patients often present with estab-
lished lung inflammation, and interventions must therefore be
guided toward this second phase of neutrophil recruitment to
reduce lung injury and ventilator dependence. The underlying
cellular mechanisms driving this second phase of neutrophil re-
cruitment remain to be fully characterized.
Peripheral blood monocytes (PBMs) are recruited alongside
neutrophils in acute inflammation (6–10), and their potential
importance in regulating and amplifying the inflammatory re-
sponse is increasingly recognized (11, 12). Chemokine gener-
ation from recruited monocytes is implicated in effecting
neutrophil recruitment (12, 13). These descriptions, alongside
the recent discovery of patrolling sentinel monocytes within
the vasculature (6), highlight PBMs’ potential role in sensing
and directing the inflammatory response. The importance of
PBMs in acute inflammation offers a potential therapeutic
window because they mobilize from the bone marrow and cir-
culate in the peripheral vasculature before tissue infiltration in
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Peripheral blood monocytes have been implicated in the
pathogenesis of acute lung injury (ALI), but little is known
of their contribution to ongoing neutrophil influx in the
persistent phase of ALI.
What This Study Adds to the Field
This study provides evidence in a preclinical model of ALI
that monocytes play a critical role in the later stages of
neutrophil influx and that their temporal targeted depletion
is a potential therapeutic strategy.
ALI (14–16). Hence, targeting PBMs and the mechanisms
by which they could influence neutrophil emigration may pro-
vide a valuable interventional strategy. This study aimed to
investigate the utility of such an approach in a murine ALI
model generated by the direct intratracheal administration of
bacterial LPS.
To our knowledge, therapeutic depletion of PBMs timed to
occur in the established phase of murine ALI has not previously
been reported. Delineating the role of the PBM independently
from its tissue descendents in the mononuclear phagocyte sys-
tem (MPS) has been difficult. The majority of published models
investigating depletion in the MPS system in vivo affect PBMs
and tissue-resident macrophages (17–19). Indeed, studies have
highlighted the role played by the resident alveolar macro-
phage (AM) in eliciting the inflammatory response in ALI
through orchestration of early chemokine responses (20, 21).
In contrast to models used to study anatomical compartments
such as the peritoneum and pleura (18, 19), it is possible to
selectively ablate the PBM compartment without affecting
resident AMs in murine models of lung inflammation (22).
We used three independent techniques to deplete PBMs:
systemic liposomal clodronate (sLC), diphtheria toxin (DT)
administration in CD11b diphtheria toxin receptor (DTR)
mice, and targeted antibody-dependent cell–mediated cytotoxic
(ADCC) depletion of monocytes (Table 1). Resident AM pop-
ulations are unaffected by these three techniques. Compartmen-
tal AM depletion and lung macrophage replenishment studies
confirmed that the attenuation of neutrophil recruitment was
independent of possible effects on the AM population. This
study therefore demonstrates the efficacy of temporal, targeted
depletion of PBMs in established murine ALI. Some of the
results of these studies have been previously reported in the
form of an abstract (23).
METHODS
Animals
Adult (25–35 g) specific pathogen-free BALBc/CD1/C57BL/6 mice and
CD11b-DTR mice (FVB/N and C57BL/6 genetic background) were
used. All studies were done under UK Home Office licenses 60/3545
and 60/3797.
LPS Lung Injury and BALF Retrieval
Unless otherwise indicated, 10 mg LPS from Escherichia coli (serotype
O111:B4; Sigma-Aldrich, St. Louis, MO) in 50 ml PBS was given intra-
tracheally. BALF was collected and weighed 48 hours later, and cell
counts were adjusted per microliter of BALF retrieved. Cells were
fixed and stained using a Quik-Diff kit (Reagena, West Sussex, UK),
and differential counts were determined.
Neutrophil Depletion
Neutrophil depletion (24) was achieved using monoclonal anti-mouse
Ly-6G Ab (IA8 clone, rat IgG2a; BioXCell, West Lebanon, NH). Mice
were given two injections of 1 mg Ly-6GAb or isotype control in 100 ml of
sterile saline intraperitoneally 6 and 24 hours after lung injury induction.
Monocyte Depletion
Liposomal clodronate. Liposomal clodronate (LC) was a gift of Roche
Diagnostics GmbH (Mannheim, Germany). It was encapsulated in lipo-
somes as previously described (25). LC or liposomal PBS (400 ml of
each) were administered intraperitoneally 6 hours after intratracheal
LPS, and a further 200 ml was administered 18 hours later. For AM
depletion, 100 ml of LC or liposomal PBS were administered intra-
tracheally 48 hours before intratracheal LPS.
DT in CD11b-DTR. DT (10 ng/g) (18, 19) was administered 6 and 24
hours after intratracheal LPS. For adoptive cell add-back experiments,
age-, strain-, and sex-matched animals were used as controls, and DT was
administered at the same intervals as described above.
MC21 monoclonal antibody. The CCR2-specific antibody MC21
(IgG2b) (20 mg) (26) was administered intraperitoneally 6 and 24 hours
after intratracheal LPS. Control animals received isotype (IgG2b, clone
141945, MAB0061; R&D Systems, Minneapolis, MN).
Flow Cytometry Methods
Flow cytometry methods, including assessment of neutrophil transendo-
thelial migration, are detailed in the online supplement.
Lung MPO Activity
Lung MPO activity was determined as previously described (27). Lung
vascular permeability was determined as previously described (28) and
is described further in the online supplement. Gravimetric determina-
tion of lung edema is described in the online supplement.
ELISA
ELISA kits for measurement of IL-10, SDF-1, and KC in BAL fluids
(DuoSet; R&D Systems) were used according to the manufacturer’s
protocols.
In Vivo Optical Imaging
In vivo optical imaging was performed on the KodakMS FX Pro (Kodak
Carestream, Rochester, NY) and the Visen FMT 2500 (Perkin-Elmer,
Waltham, MA) as previously described (29). For vascular leak, 1.5 nmol
of SAIVI albumin 680 (Invitrogen, Paisley, UK) was injected via the
TABLE 1. SUMMARY OF PERCENTAGE REDUCTION OF ALVEOLAR NEUTROPHILS AFTER MONOCYTE
DEPLETION IN LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY
Systemic Clodronate DT in CD11b-DTR MC21 mAb
LPS (neutrophils/ml BAL) 3,561 6 692.3 2,036 6 413.9 2,488 6 361.4
LPS plus treatment (neutrophils/ml BAL) 650.6 6 135.9 408.6 6 154.3 1,511 6 177.0
P value 0.0036 0.0040 0.0182
Neutrophil differential of total cell count (LPS alone is 83%) 70% 57% 76%
% Reduction from control 82 80 39
% Total monocyte reduction in peripheral blood 70 95 35
% Gr-1hi reduction 74 95 74
% Gr-1lo reduction 53 90 4
Definition of abbreviations: BAL ¼ bronchoalveolar lavage; CD11b-DTR ¼ CD11b diphtheria toxin receptor mice; DT ¼
diptheria toxin; Gr-1 ¼ granulocyte-1; mAb ¼ monoclonal antibody.
LPS (10 mg) was instilled intratracheally, followed 6 and 24 h later by monocyte depletion treatments. Data show alveolar
neutrophil counts at 48 h after LPS instillation with and without treatment in representative experiments. The average cell
differentials were determined in BAL for neutrophils and mononuclear cells. LPS alone had a 83% neutrophilia in BAL. The
efficiency of peripheral blood monocyte depletion was evaluated by serial blood analysis, and data show total and subset
reductions.
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lateral tail vein, and animals were imaged 30 minutes later. For lung
protease activity, 1 nmol of a cathepsin-activatable probe (Prosense
750; Perkin-Elmer) or PBS control was instilled intratracheally 12 hours
after intratracheal LPS. Images were acquired 24 hours after Prosense
administration.
Cell Isolations
Bone marrow–derived macrophages (BMDMs) were harvested and
generated from 8- to 12-week-old female mice as described previously
(27). Viable cells (1 3 106) were instilled intratracheally 24 hours after
intratracheal LPS. For intravenous reinfusions, 5 3 106 viable cells
were administered by intravenous tail vein injection at 6 and 24 hours
after intratracheal LPS. Mononuclear cell (MNC) isolation is de-
tailed in the online supplement and is based on a published method
(30). Cells (5 3 106) were infused intravenously 6 and 24 hours after
intratracheal LPS. Lymphocyte controls were generated by negative
magnetic selection using CD11b microbeads (Miltenyi Biotec, Sur-
rey, UK). For optical imaging, cells were labeled with DiR (10 mM in
PBS) (Invitrogen, Paisley, UK) (31).
Histology and F4/80 Immunohistochemistry
Histology and F4/80 immunohistochemistry were performed as previ-
ously described in subsets of animals without prior BAL (32). Histol-
ogy scoring was conducted by a blinded observer (33).
Statistics
Student’s t test and Mann-Whitney U test were used for comparisons
between two groups and one-way ANOVA with Bonferroni’s post hoc
test for greater than two groups. For sequential samples, repeated mea-
sures two-way ANOVA with Bonferroni’s post hoc test was used. All
analyses were conducted using GraphPad prism (V5.0, La Jolla, CA). In
all data presented, *P < 0.05, **P < 0.01, ***P < 0.001.
RESULTS
Characterization of LPS-induced Lung Injury
ALPS-mediatedmodel of lung injury was used (see Figure E1 in the
online supplement) with intratracheal delivery of LPS. Maximum
lung injury was observed at 48 hours, and the peak neutrophil count
was observed at 24 hours. To demonstrate the continued influx of
neutrophils between 12 and 48 hours after insult in this model, we
used the neutrophil-specific depleting monoclonal antibody (mAb)
Ly-6G (IA8 clone) (24). Systemic administration of the mAb 12
hours after LPS instillation yielded a 60% reduction in mean alve-
olar neutrophil count in bronchoalveolar lavage fluid (BALF) re-
trieved at 2 days (Figure E1). Forty-eight hours was chosen as the
time point for BALF retrieval and tissue analysis in all further
murine experimentation because it afforded time to apply thera-
peutic interventions after LPS administration and corresponded to
maximal vascular leak and extravasated total protein in BALF.
Peripheral Administration of LC Depletes PBMs
and Attenuates ALI
sLC has been shown to deplete 90% of PBMs within 24 hours in
mice (25, 34) and tissue macrophages in the spleen and liver. In
preliminary studies, biodistribution of fluorescently labeled sLC
showed accumulation in the liver, spleen, and bone marrow with
minimal accumulation in the lungs (Figure E2). Consistent with
the biodistribution studies, F4/80-positive hepatic (112.7 6 8.4
Figure 1. Characterization of the sys-
temic administration of systemic liposo-
mal clodronate (sLC). (A) sLC induces
widespread resident F4/80 macrophage
depletion in spleen and liver (original
magnification: 3200) with no effect on
resident alveolar macrophages (original
magnification: 340) compared with PBS
liposomes (PBS L) (F4/80 staining indi-
cated by brown color). (B) sLC does not
affect blood neutrophil numbers in naive
mice compared with PBS L (i.e., mice
that have not been given LPS) (n ¼ 7
per group). Data are presented as mean
and 95% confidence interval. Not signif-
icant (P ¼ 0.323) by Student’s t test.
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vs. 4.66 6 0.88 [mean 6 SEM] cells per high-power field; P ¼
0.0003 by Student’s t test) and splenic (35.69 6 1.9 vs. 5.55 6
0.223 percentage of area of F4/80 staining per high power field
determined on Image J; P , 0.0001 by Student’s t test) macro-
phages were ablated by sLC (Figure 1A) compared with ani-
mals receiving PBS liposomes. sLC did not reduce peripheral
blood neutrophils (Figure 1B) or AM numbers retrieved from
BALF (Figure E2). sLC did not lead to significant elevations in
inflammatory cytokines in BALF (data not shown). The tempo-
ral depletion of PBMs using sLC is well characterized, with
a nadir at 6 to 8 hours after LC administration with recrudes-
cence of Gr-1hi PBMs 18 hours later (34, 35). Hence, two sequen-
tial doses of intraperitoneal LC (6 and 24 h after LPS insult) were
used to ensure sustained PBM depletion (Figure 2B). F4/80
staining of lungs in LPS-treated mice receiving PBS liposomes
showed prominence of F4/80-positive infiltrating monocytes. In
contrast, in sLC-treated animals, resident AMs were evident with
reduced influx of F4/80-positive cells (Figure 2B). Histological as-
sessment of lungs at 48 hours (Figure 2B) showed reduced neutro-
phil ingress and lung injury. Blinded scoring of histology showed
a significant reduction in injury score (12.50 6 0.76 vs. 6.0 6 0.33;
P , 0.0001 by Student’s t test). PBM depletion after LPS admin-
istration significantly attenuated neutrophil numbers in BALF at
48 hours (Figure 2C). Additionally, total protein in BAL fluid
(Figure 2D), lung edema (Figure 2E), and pulmonary vascular
permeability were significantly reduced (Figure E2).
LC Delivered Locally to the Lung Depletes AMs but Does Not
Attenuate ALI
In contrast to sLC, compartmental pulmonaryLCdelivery depletes
AMs (32) (Figure E3) without having systemic effects. In keeping
Figure 2. Peripheral blood monocyte depletion with systemic liposomal clodronate (sLC) attenuates acute lung injury (ALI). (A) sLC administered 6
and 24 hours after intratracheal LPS. sLC induces the depletion of granulocyte-1 (Gr-1)hi and Gr-1lo peripheral blood monocytes (PBMs) in the
context of ongoing LPS-induced pulmonary inflammation. Left panel of each represents forward (cell size) and side (granularity) scatter plots (FSC/
SSC plots) and the gating strategy for mononuclear cells. Right panels show CD11b versus Gr-1 staining of mononuclear cells in peripheral blood of
mice showing depletion of CD11bhi Gr-1hi and Gr-1lo monocytes in mice receiving sLC. Double-positive cells reduce from 4.93 to 2.44%.
Representative flow plot of n ¼ 5. (B) sLC administered 6 and 24 hours after intratracheal LPS results in reduced histologic features of ALI and
reduced infiltration of F4/80 PBMs (brown staining) into the lung. Original magnification: 340. Representative of n ¼ 3. (C) sLC markedly
significantly reduced LPS-induced bronchoalveolar lavage fluid (BALF) neutrophilia at 48 hours. Data are presented as mean and 95% confidence
interval (CI). Significant by Student’s t test (P ¼ 0.0005; n ¼ 10 per group). (D) Accompanying the reduced neutrophil influx, there was reduced
total protein in BALF in clodronate liposome (CLOD L)-treated mice compared with PBS L–treated mice, reflecting a reduction in epithelial-
endothelial injury (n ¼ 5 mice per group). Data are presented as mean and 95% CI. P ¼ 0.028 by Student’s t test. (E) sLC signficantly reduced
lung edema at 48 hours measured by wet/dry ratios of whole murine lungs after drying for 3 days in a 608C oven. Data are presented as mean and
95% CI. Significant by one-way ANOVA and Bonferroni’s post test. Overall P value , 0.0001 (n ¼ 5 mice per group).
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with previous studies in rodents (36, 37), prior compartmental
depletion of resident AMs did not reduce experimental pulmo-
nary inflammation (Figure E3).
Characterization of the CD11b-DTR Mouse for PBM
Depletion in ALI Models
To refine PBM depletion, we characterized ALI in the CD11b-
DTR mouse, which expresses human DTR from CD11b pro-
moter sequences, directing transgene expression to monocytes/
macrophages after administration of very low concentrations of
DT (18). A range of DT doses were tested in vivo, with 10
ng/g showing reduction of PBM by 90%. Despite the presence
of CD11b on neutrophils, DT administration to CD11b-DTR
mice did not affect the ability of granulocytes to up-regulate
CD11b in response to LPS (Figure 3A) or neutrophil counts
(Figures 3B–3D). BALF cells characterized morphologically
as AMs retrieved from CD11b-DTR mice were phenotypi-
cally CD11blo and CD11chi, explaining their resistance to
DT (Figure 3E). Similar to the effects of sLC treatment,
DT administration to CD11b-DTR did not affect the numbers
of AMs in BALF (Figure 3F). However, in contrast to sLC,
Figure 3. Characterization of the systemic administration of diphtheria toxin (DT) in the CD11b-DTR mouse. (A) Neutrophils were gated in whole
blood based on their characteristic FSC/SSC profile. CD11b expression was then assessed on the gated neutrophils. Representative histogram plot of
CD11b expression on whole neutrophils in murine blood. Whole blood was incubated with 100 ng/ml of Escherichia coli LPS for 30 minutes and then
stained and analyzed for CD11b expression. CD11b is up-regulated on blood neutrophils from CD11b-DTR mice that had two doses of DT to the
same degree as CD11b-DTR mice that had PBS control (n ¼ 3 mice per group). (B) Bone marrow neutrophils were identified by flow cytometry in
whole marrow perfusates by CD11b and Ly6G antibody staining. (C) Percentage of neutrophils in marrow perfusates from CD11b-DTR mice given
DT or PBS control shown as percentage of total cells in marrow (n ¼ 3 mice per group). Data are presented as mean and 95% confidence interval
(CI). Not significant (P ¼ 0.2) by Mann-Whitney test. (D) Peripheral blood neutrophils are not depleted after intraperitoneal DT in CD11b-DTR mice.
Whole blood was analyzed by flow cytometry for neutrophil count on Day 1 and Day 2 of after DT treatment in naive mice. Data are presented as
mean and 95% CI. Not significant (P ¼ 0.4245) by repeated measures two-way ANOVA (n ¼ 3 mice per group). (E) Alveolar macrophages (AMs)
from CD11b-DTR mice express low/absent levels of CD11b and are CD11chi. (F) DT administered to CD11b-DTR mice does not affect the number of
AMs in bronchoalveolar lavage fluid. Data are presented as mean and 95% CI. Not significant (P ¼ 0.5614) by Mann-Whitney test (n ¼ 3 mice per
group). (G) Representative histology in CD11b-DTR mice receiving DT. F4/80 (brown staining) macrophages remain in spleen (original magnifica-
tion: 3200), liver (3200), and lung (340).
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DT administration to CD11b-DTR mice did not ablate he-
patic cells (95.4 6 16.36 vs. 92.20 6 11.89 cells per high-power
field; P ¼ 0.82 by Student’s t test) and had a much reduced
depletion effect on splenic F4/80 staining (35.69 6 1.9 vs.
17.47 6 0.96 percentage of area of F4/80 staining per high-
power field determined on Image J; P ¼ 0.0011 by Student’s
t test) (Figure 3G).
DT Administration in CD11b-DTR Mice Attenuates ALI
Having established that DT administration ablated blood
monocytes (Figure 4A) (but not hepatic cells, AMs, or blood
or bone marrow neutrophils) in vivo, we used the CD11b-DTR
mouse to investigate the role of the PBM in ALI. PBM ablation
using two consecutive doses of DT (10 ng/g) at 6 and 24 hours
after LPS administration significantly attenuated neutrophil
Figure 4. Peripheral blood monocyte (PBM) depletion in the CD11b-DTR mouse reduces ALI as evidenced by decreased neutrophil numbers,
vascular leak, inflammatory cytokines, and improved oxygenation. (A) Diphtheria toxin (DT) in the CD11b-DTR mouse induces the depletion
of granulocyte-1 (Gr-1)hi and Gr-1lo PBMs in the context of ongoing LPS-induced pulmonary inflammation. Left panel of each represents FSC/
SSC plots and gating strategy for mononuclear cells. Right panels show CD11b versus Gr-1 staining of mononuclear cells in peripheral blood of
mice showing an absence of CD11bhi Gr-1hi and Gr-1lo monocytes in mice receiving DT versus PBS. Representative flow plots of n ¼ 5 mice.
Double-positive cells reduced from 9.24 to 1.73%. (B) In CD11b-DTR mice receiving intratracheal LPS, two doses of 10 ng/g DT led to reduced
histological features of ALI and reduced infiltration of F4/80-positive (brown staining) PBMs with retained alveolar macrophages. (C) At 48
hours after LPS, there was a marked reduction in neutrophil numbers in bronchoalveolar lavage fluid (BALF) (n ¼ 7 mice per group) in DT-
treated CD11b-DTR mice compared with control mice. Data are presented as mean and 95% confidence interval (CI). P ¼ 0.0003 by t test. (D)
Accompanying the reduced neutrophil influx, there was reduced total protein in BALF in DT-treated CD11b-DTR mice compared with control
mice, reflecting a reduction in epithelial-endothelial injury (n ¼ 7 mice per group). Data are presented as mean and 95% CI. P ¼ 0.029 by t
test. (E) Stromal-derived factor-1 (SDF-1) was significantly decreased in BALF from CD11b-DTR mice receiving DT compared with control mice
(n ¼ 7 mice per group). Data are presented as mean and 95% CI. P ¼ 0.0145 by t test. (F) IL-10 was significantly increased in BALF from
CD11b-DTR mice receiving DT compared with control mice (n ¼ 7 mice per group). Data are presented as mean and 95% CI. P ¼ 0.013 by t
test. (G) Top panel: Whole body reflectance imaging of mice after intravenous-labeled albumin showing reduced airway accumulation of
albumin in the LPS-DT animal on the right in comparison to the PBS-DT animal on the left (representative animal from n ¼ 3 per group that
were imaged). Bottom panel: Cathepsin activity (measured 24 h after administration of Prosense 750) is also reduced in murine lungs after DT
treatment (comparing LPS-DT mouse on the right with LPS-PBS mouse on the left). (H ) In mice receiving 100 mg of LPS intratracheally followed
by DT, at 48 hours there is significant improvement in oxygenation (n ¼ 4 mice per group). Data are presented as mean and 95% CI. P ¼ 0.028
by Mann Whitney test.
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recruitment (Figures 4B and 4C). Histological assessment
showed reduced lung injury and inflammatory infiltrates (Fig-
ure 4B). Blinded scoring of histology showed a significant re-
duction in injury score (12.30 6 1.2 vs. 7.0 6 0.17; P , 0.001 by
Student’s t test). F4/80 staining of lungs showed reduced pulmo-
nary ingress of monocytes with retained AMs (Figure 4B), and
BALF analysis showed significantly reduced neutrophil num-
bers (Figure 4C) and total protein (as a measure of alveolar-
endothelial disruption) (Figure 4D). There was no difference in
the concentration of the key neutrophil chemokine KC in
BALF at 48 hours by ELISA (data not shown). However, the
recently characterized neutrophil chemokine SDF-1 was signif-
icantly reduced in mice that had received monocyte depletion
by administration of DT (Figure 4E). Furthermore, lavage cyto-
kines from these animals showed an antiinflammatory pheno-
type with increased IL-10 in monocyte-ablated animals (Figure
4F). Noninvasive whole-body optical imaging of treated mice
also demonstrated a striking reduction in pulmonary vascular
leak and protease activity (Figure 4G). Oxygenation of mice was
assessed by performing arterial blood gas measurements in mice
receiving 100 mg of LPS followed by monocyte depletion. This
demonstrated significantly improved oxygenation (Figure 4H).
Pulmonary vascular permeability and lung function were also im-
proved (Figure E2).
DT Administration in CD11b-DTR Mice Attenuates Neutrophil
Recruitment in a Model of Live Bacterial Infection
To evaluate if neutrophil recruitment was dependent on mono-
cytes in a model of direct bacterial instillation, we delivered 105
colony-forming units of Pseudomonas aeruginosa followed by
DT administration in the CD11b-DTR mouse. In this model,
mice were lavaged 18 hours after bacterial instillation. There
was a significant (P ¼ 0.0002) reduction in alveolar neutrophil
numbers but no significant difference in recoverable bacteria in
BALF (Figure E4).
Targeted Depletion of CCR2hi (Gr-1hi) PBMs Results in
Attenuation of Neutrophil Numbers in BAL at 48 Hours
sLC in wild-type mice and DT in the CD11b-DTR resulted in
Gr-1hi and Gr-1lo PBM depletion. To test whether the effect was
specific to particular PBM subtypes, we used low doses of an
anti-CCR2 monoclonal antibody (MC21) to specifically deplete
CCR2hi Gr-1hi PBMs (26). Preliminary studies confirmed that
this dose of MC21 did not lead to peripheral blood neutrophil
depletion in naive mice (n ¼ 3 mice per group receiving 20 mg of
MC21 or isotype control and neutrophil percentage in whole
blood was analyzed the following day; P ¼ 0.7 using Mann-
Whitney test). MC21 mAb (20 mg/mouse) was administered
6 hours after intratracheal LPS and then repeated 24 hours to
maintain Gr-1hi monocyte depletion (Figures 5A–5C). MC21
administration to LPS-treated mice resulted in a significant
attenuation of neutrophil numbers in BALF (Figure 5D) and
reduced myeloperoxidase (MPO, a neutrophil marker) in whole
lung homogenates (Figure 5E) in comparison to isotype-treated
control mice. In MC21-treated mice, there was a trend for a re-
duction in total BALF protein (Figure 5F). SDF-1 and pulmonary
vascular permeability (Figure E2) were significantly reduced in
MC21-treated mice.
PBM Depletion Reduces Pulmonary Vascular Permeability
and Improves Indices of Ventilation
All of the PBM depletion methods significantly reduced pulmo-
nary vascular leak measured by Evans blue (28) (Figure E2).
Mice were subjected to whole-body plethysmography to record
an index of ventilation. DT in the CD11b-DTR significantly im-
proved an index of ventilation (Figure E2).
PBM Depletion Reduces Pulmonary Interstitial Neutrophils
Having demonstrated the reduced alveolar neutrophil influx after
PBM depletion, we wished to determine if the pulmonary intersti-
tial pool of neutrophils was reduced. Using methods recently de-
scribed (38), we identified neutrophils in lung homogenates by
dual staining for Ly6G and CD11b (Figure E6). Fluorescently
labeled antibody against granulocyte-1 (Gr-1) was injected intra-
venously and served as a marker for intravascular neutrophils
(CD11b1, Ly6G1, and Gr-11). DT administration in CD11b-
DTR mice and sLC in wild-type mice significantly reduced the
total percentage of pulmonary interstitial neutrophils (Figure E6),
suggesting a role for PBMs in transendothelial migration as re-
cently described (39).
Adoptive Intravenous Transfer of Mononuclear Cells but Not
Macrophages Restores LPS-mediated Lung Inflammation
To confirm that selective depletion of PBMs was responsible
for the attenuation of neutrophil numbers in BAL, adoptive
transfer experiments were performed. CD11b-DTR mice re-
ceived intratracheal LPS at time 0 and intraperitoneal DT at
6 and 24 hours after LPS but also received adoptive transfer
of various primary cells (obtained from syngeneic wild-type
mice). Compartmental (pulmonary) and intravenous repletion
studies were performed.
Compartmental pulmonary delivery of BMDMs to the LPS-
treated lung afterDT treatment had no affect onBALneutrophil
count at 48 hours (data not shown). Two infusions of intravenous
primary murine BMDMs (53 106) were then given to DT-treated
mice with established LPS injury, which also failed to rescue neu-
trophil numbers in BALF (815 6 201 neutrophils/ml BALF in
wild-type mice receiving LPS and DT vs. 213 6 46 neutro-
phils/ml BALF in DT-treated CD11b-DTR mice with LPS-
induced ALI and macrophage infusion; P ¼ 0.034 by Student’s
t test; n ¼ 5 per group). In contrast, intravenous adoptive trans-
fer of freshly isolated wild-type MNCs (5 3 106) resulted in an
increase of neutrophil numbers in BALF (Figure 6A) and a
highly significant rescue of neutrophil numbers measured by flow
cytometric Ly6G staining of single-cell suspensions of whole mu-
rine lungs (overall P, 0.0001) (Figure 6B). Lymphocytes isolated
by negative magnetic selection from MNCs acted as cellular con-
trols. Infusion of lymphocytes did not restore BALF or blood
neutrophilia. Infused, labeled MNCs trafficked to the inflamed
lung, to the liver, and to the spleen. In contrast, infused, labeled
lymphocytes trafficked to liver and spleen but not to the inflamed
lung (Figure E6).
Monocyte infiltration and dendritic cell (DC) maturation in the
murine LPS–inflamed lung has been recently characterized, and
MHC IIhi CD11chi CD11bhi myeloid infiltrating DCs are potent
producers of neutrophil chemokines (40). We therefore investi-
gated expression of CD11b on monocytoid subsets in lung tissue.
There was a significant increase in CD11b expression on lung
CD11chi, MHC IIhi cells in monocyte-depleted CD11b-DTR
LPS-treated mice receiving MNC infusions (Figure 7), with par-
tial rescue toward levels observed in LPS-treated wild-type mice,
in marked contrast to those receiving lymphocytes.
DISCUSSION
Studies using rodent models of ALI demonstrate that the early
influx of neutrophils is primarily directed by cytokine gradients
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generated from resident lung leukocytes and epithelial cells
(41–43). This directs intraalveolar movement of neutrophils
from the marginated pool within the lung and from the initial
wave of bone marrow–mobilized neutrophils in the circulation
(24). However, as we and others have shown, this initial wave of
neutrophil-specific murine cytokines (KC, MIP-2) declines rap-
idly (18), and the factors controlling the sustained response
remain unclear. Recent work implicates pulmonary epithelial
cell–produced SDF-1 in later phase neutrophil recruitment
(5), but the role of the innate immune cellular response in reg-
ulating the ongoing neutrophil influx is not clearly defined.
PBMs are increasingly being recognized in many organ systems
as orchestrators of leukocyte recruitment (11, 22), prime
initiators of endothelial damage (44, 45), and pivotal contribu-
tors to fibrogenesis (32, 46). However, despite the significant
body of work suggesting that monocytes contribute to ALI
(11, 13, 16, 39, 44, 45, 47–49), no published reports exist of
therapeutic monocyte depletion in established experimental
ALI. We hypothesized in this study that infiltrating PBMs play
a major role in regulating ongoing neutrophil recruitment and
consequent vascular leak and that depletion of the PBM pool is
a therapeutic target in the setting of established ALI.
Given the controversy regarding the role of PBMs in ALI,
we used three independent techniques in a LPS-induced ALI
model, specifically aimed at investigating the function of PBMs
in regulating the persistent phase of neutrophil recruitment in
Figure 5. Specific granulocyte-1 (Gr-1)hi CCR2hi monocyte depletion results in a reduction in neutrophil numbers in bronchoalveolar lavage fluid
(BALF) at 48 hours after experimental acute lung injury. (A) Representative flow plots of murine whole blood 24 hours after MC21 monoclonal
antibody (mAb) administration shows specific depletion of Gr-1hi PBMs in the setting of LPS-induced acute lung injury. The left panel for each
condition represents FSC/SSC plots and gating strategy for mononuclear cells. Right panels show CD11b versus Gr-1 staining of mononuclear cells in
peripheral blood of mice showing the absence of CD11bhi Gr-1hi monocytes in mice receiving MC21 versus isotype control. Double positives
reduced from 7.14 to 0.42%. (B) Quantification of Gr-1lo monocytes in whole blood 24 (Day 1) or 48 hours (Day 2) after LPS shows no difference in
animals receiving MC21 versus isotype control mice. Data are presented as mean and 95% confidence interval (CI) (n ¼ 10 per group). ns ¼ not
significant (P ¼ 0.633) by repeated measures two-way ANOVA. (C) Quantification of Gr-1hi monocytes in whole blood 24 (Day 1) or 48 h (Day 2)
after LPS are significantly decreased with MC21 administration, as quantified by flow cytometry. Data are presented as mean and 95% CI (n ¼ 10
per group). P , 0.0001 by repeated measures two-way ANOVA. (D) Forty-eight hours after intratracheal LPS, neutrophils are reduced in BALF from
mice treated with MC21 mAb compared with isotype-treated control mice (n ¼ 10 per group). Data are presented as mean and 95% CI. P ¼ 0.011
by t test. (E) Myeloperoxidase (MPO) is reduced in whole lung homogenates from LPS-treated mice receiving MC21 mAb, compared with isotype-
treated control mice expressed as optical density (450 nm) of MPO substrate (n ¼ 10 mice per group). Data are presented as mean and 95% CI. P ¼
0.0327 by t test. (F) Accompanying the reduced neutrophil influx, there was a nonsignificant trend for reduction in total protein in BALF in treated
mice (n ¼ 5 mice per group). Data are presented as mean and 95% CI. P ¼ 0.07 by Student’s t test. (G) SDF-1 was significantly reduced in BALF in
monocyte-depleted mice (n ¼ 6 per group). Data are presented as mean and 95% CI. P ¼ 0.0379 by t test.
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ALI. In each case, treatments were administered for two con-
secutive days to ensure sustained depletion of PBMs (34, 35).
Caveats for each individual depletion technique exist, but the
observation that all three depletion strategies significantly at-
tenuated neutrophil numbers in BALF (Table 1) in established
ALI supports the general supposition.
The first technique we used was sLC administration. sLC has
been extensively used in the literature to specifically deplete
cells of the MPS (25). However, there have been few attempts
to deplete PBMs in models of ALI using sLC (49, 50). These
prior studies used early time points and showed no significant
effects on neutrophil recruitment to the acutely inflamed lung
but did not address later phase responses. A recent study using
sLC depletion supported a role for monocytes in the transendo-
thelial migration of neutrophils in an ischemia-reperfusion lung
injury model (39), supporting our findings.
The treatment protocol we used resulted in a 70% reduction of
PBMs (Gr-1hi and Gr-1lo subsets) without affecting resting neu-
trophils or resident AMs. However, there was also substantial
ablation of hepatic and splenic macrophage pools and a conse-
quent increase in the circulating number of neutrophils in the
ALI model (data not shown). sLC resulted in a significant de-
crease in LPS-mediated neutrophil count in BALF at 48 hours.
This divergent phenotype of decreased tissue neutrophils in the
presence of significantly elevated blood neutrophilia closely
resembles previous studies in an antiglomerular basement mem-
brane model of renal injury (51). It is possible that the increased
numbers of circulating neutrophils was due to their inadequate
clearance by liver and splenic macrophages, which are depleted
with sLC. Irrespectively, our observations suggested a major
role for the PBM and/or its tissue descendents in the recruitment
of neutrophils from the blood to the lung during the “persistent
phase” of ALI.
We therefore used the transgenic CD11b-DTR mouse (18,
19), an inducible system with significantly less hepatic/splenic
macrophage depletion (Figure 3G). In the setting of ALI, this
transgenic system offers an effective means by which to specif-
ically deplete Gr-1hi and Gr-1lo PBM subsets. Unlike other
tissue-resident macrophages, AMs are resistant to depletion ow-
ing to their low or absent expression of CD11b (Figure 3) (22),
and neutrophils are not affected (18, 52, 53). Using this method
for therapeutic PBM depletion in established murine ALI, there
was a significant reduction in pulmonary neutrophil numbers in
BALF at 48 hours. This corresponded with histological evidence
of reduced lung injury (Figure 4B) and a significant reduction in
SDF-1 in BALF. In the peripheral blood there was a significant
reduction in neutrophilia, suggesting that the mobilization of
neutrophils from bone marrow was reduced (data not shown).
Given that the pulmonary production of SDF-1 is now recog-
nized as a potential regulator of ongoing neutrophil recruitment
to the inflamed lung, these findings suggest PBMs may contrib-
ute directly or indirectly to pulmonary SDF-1 expression.
sLC in wild-type mice and DT administration in CD11b-DTR
mice led to depletion of the Gr-1hi and Gr-1lo monocyte subsets.
Gr-1hi monocytes express CCR2 and have been described as the
prime inflammatory monocyte subset (54). To determine if this
subset contributed significantly to neutrophil influx, we used
a low-dose antimurine CCR2 mAb that was unlikely to fully
block the CCR2 axis (26) yet demonstrated direct ADCC of
peripheral CCR2-expressing cells. This intervention resulted in
Figure 6. Monocyte repletion in CD11b-DTR mice re-
sults in a partial rescue of LPS-induced pulmonary neu-
trophilia. Wild-type (WT) and CD11b-DTR mice received
10 mg of intratracheal LPS followed by two intraperito-
neal doses of 10 ng/g diphtheria toxin (DT). Mononu-
clear cells (MNCs) (or controls) were administered
intravenously on two occasions (5 3 106 cells), and
bronchoalveolar lavage fluid (BALF) was performed at
48 hours. (A) MNCs partially rescued neutrophil num-
bers in BALF at 48 hours, whereas lymphocytes (LOs)
did not. Data are presented as mean and 95% confi-
dence interval (n ¼ 5 per group). Not significant by
one-way ANOVA and Bonferroni’s post test. Overall
P value ¼ 0.096. (B) Single cell digests of lungs of mice
from the same experiment showed a reduction in the
percentage of Ly6G cells, which was partially rescued by MNC infusion. Data are presented as mean and 95% confidence interval (n ¼
5 per group). Analyzed by one-way ANOVA and Bonferroni’s post test. Overall P value , 0.0001.
Figure 7. Monocyte repletion in CD11b-DTR
mice results in a partial rescue of a LPS-induced
population of pulmonary monocytoid cells ex-
pressing CD11b/MHC II. Wild-type (WT) and
CD11b-DTR mice received 10 mg of intratracheal
LPS followed by two intraperitoneal doses of
10 ng/g diphtheria toxin (DT) at 6 and 24 hours
after LPS. Mononuclear cells (MNCs) (approxi-
mately 30% of which are monocytes) or lympho-
cytes (LOs) were administered intravenously on
two occasions at 6 and 24 hours after LPS, and
lungs were harvested at 48 hours. (A) Monocy-
toid cells resembling dendritic cells (DCs) were
characterized in whole lung digests by CD11c
and MHC II expression (left panel gate). (B) Geo-
metric mean of CD11b expression on gated cells
was partially but significantly rescued by intravenous MNC infusion. Data are presented as mean and 95% confidence interval. Analyzed by
one-way ANOVA and Bonferroni’s post test. Overall P value ¼ 0.003 (n ¼ 5 per group).
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a 95% reduction in Gr-1hi monocytes and led to a less striking
reduction in pulmonary neutrophilia at 48 hours when compared
with depletion of the Gr-1hi and Gr-1lo subsets. A caveat for this
depletion methodology is that neutrophils do express CCR2. We
showed in preliminary studies that low-dose MC21 did not de-
plete naive murine neutrophils; however, this does not preclude
depletion during inflammation because neutrophil CCR2 may
be up-regulated, thereby increasing susceptibility to ADCC.
The question of whether AMs contributed to the reduction
in neutrophil numbers in BALF was addressed by performing
local compartmental ablation of resident AMs. This resulted
in a trend for an increase in neutrophil numbers (not statistically
significant) in BALF at 48 hours in mice receiving 10 mg of LPS
in comparison to control ALI mice (Figure E3). This is similar
to findings describing that depletion of AMs increases neutro-
phil recruitment (55). Indeed, these studies further support our
contention that the AM is not directing the ongoing influx of
neutrophils; rather, circulating monocytes are responsible.
Although systemic macrophage reconstitution had no pheno-
typic effect, MNC repletion partially rescued neutrophil numbers
in whole lung after LPS treatment (Figure 6). In that regard, recent
descriptions of monocyte emigration and maturation to pulmo-
nary DCs and macrophages in naive and inflammatory situations
(15, 56) highlight the possibility of targeting PBMs and impinging
on DC/macrophage maturation in acute inflammation within
the lung. Indeed, MNC rescue of neutrophil emigration in
lungs (after DT administration in LPS-induced ALI in the
CD11b-DTR mice) was associated with an inflammatory DC
phenotype in lung digests (Figure 7) (CD11chi MHC IIhi,
CD11bhi). We did not perform lineage tracing studies to prove
conclusively that myeloid-derived monocytes directly contrib-
uted to this population, but this supposition is supported by
recent studies (40).
MNCs have been administered as a therapy in murine models
of lung injury, but up to now this strategy has been applied in the
late stages of LPS-inducedALI. Indeed, Prota and colleagues (57)
assessed therapeutic efficacy at 28 days after LPS administration
and Yamada and colleagues at 1 week after LPS instillation (58).
We speculate that the acute phase of inflammation driven by
monocytes may be detrimental to the host and that late-phase
mononuclear cell recruitment may be beneficial. In that regard,
regulatory T lymphocytes (59) have been shown to be critical in
the resolution of LPS-induced ALI through promoting neutrophil
apoptosis. As such, the beneficial effects of MNC therapy in stud-
ies by Yamada and colleagues (58) and Prota and colleagues (57)
may have been mediated via lymphocytes rather than monocytes.
We show data that PBMs facilitate pulmonary neutrophil re-
cruitment in a model of live bacterial infection (Figure E4).
However, this does not preclude potentially deleterious sequalae
of PBM depletion in the setting of infection given the pleiotro-
pic immunomodulatory functions of Gr1hi and Gr-1lo monocyte
subsets (13, 14, 32, 34, 35).
In summary, we have demonstrated that PBM depletion
attenuates ALI, associated with consistent and significant reduc-
tion in neutrophil numbers in BALF and consequent tissue in-
jury. However, determining the exact point at which to target
this inflammatory response for optimal therapeutic benefit re-
mains challenging. Nevertheless, by depleting monocytes and
hence their tissue descendents in ALI, we have been able to sus-
tain an injury-attenuation effect in the “persistent” phase of ALI.
This supports the further study and development of monocyte-
targeted therapies for ALI/ARDS.
Author disclosures are available with the text of this article at www.atsjournals.org.
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